Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.67 |
| ▸ | KDM5A | P29375 | 5/20 | 0.67 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.67 |
| ▸ | PHF8 | Q9UPP1 | 10/20 | 0.57 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18579762 | 0.83 | KDM5A (0.67) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL18579812 | 0.83 | KDM4C (0.67) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL24244192 | 0.82 | KDM4C (0.69) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL16035092 | 0.81 | PHF8 (0.67) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL16032985 | 0.80 | KDM4C (1.00) | KDM4CKDM5AKDM5BKDM2BKDM4A | |
| SCHEMBL18579667 | 0.80 | PHF8 (0.64) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL18579584 | 0.80 | KDM4C (0.69) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL16033169 | 0.80 | KDM4C (0.82) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL20106599 | 0.78 | KDM4C (0.60) | KDM4CKDM5AKDM5BPHF8KDM2B | |
| SCHEMBL17604513 | 0.78 | KDM4C (0.70) | KDM4CKDM5AKDM5BPHF8KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE PHARMACEUTICALS INC (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM5A 8/4885KDM5B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.